Symbols / FEMY
FEMY Chart
About
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 32.43M |
| Enterprise Value | 35.96M | Income | -19.80M | Sales | 2.06M |
| Book/sh | 0.10 | Cash/sh | 0.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | 69 | IPO | — |
| P/E | — | Forward P/E | -1.47 | PEG | — |
| P/S | 15.73 | P/B | 5.68 | P/C | — |
| EV/EBITDA | -2.07 | EV/Sales | 17.44 | Quick Ratio | 0.49 |
| Current Ratio | 1.16 | Debt/Eq | 184.96 | LT Debt/Eq | — |
| EPS (ttm) | -0.68 | EPS next Y | -0.37 | EPS Growth | — |
| Revenue Growth | 31.40% | Earnings | 2025-11-14 16:00 | ROA | -69.37% |
| ROE | -3.76% | ROIC | — | Gross Margin | 63.05% |
| Oper. Margin | -5.01% | Profit Margin | 0.00% | Shs Outstand | 59.50M |
| Shs Float | 48.79M | Short Float | 4.30% | Short Ratio | 1.90 |
| Short Interest | — | 52W High | 1.76 | 52W Low | 0.31 |
| Beta | -2.54 | Avg Volume | 1.17M | Volume | 188.66K |
| Target Price | $5.17 | Recom | None | Prev Close | $0.55 |
| Price | $0.55 | Change | -0.91% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.17
Mean price target
2. Current target
$0.55
Latest analyst target
3. DCF / Fair value
$-3.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.55
Low
$3.00
High
$6.50
Mean
$5.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-20 | init | Laidlaw & Co. | — → Buy | $7 |
| 2025-08-11 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-06-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-05-13 | main | Jones Trading | Buy → Buy | $6 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-19 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-13 | main | Chardan Capital | Buy → Buy | $8 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-14 | main | Chardan Capital | Buy → Buy | $10 |
| 2024-08-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
- AMA procedure code supports new infertility option for over 10M US women - Stock Titan Mon, 23 Feb 2026 14
- New Analyst Forecast: $FEMY Given $6.5 Price Target | FEMY Stock News - Quiver Quantitative hu, 20 Nov 2025 08
- Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale - Yahoo Finance Wed, 27 Aug 2025 07
- Femasys Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis ue, 23 Dec 2025 08
- Femasys stock plunges after pricing public offering at steep discount - Investing.com ue, 26 Aug 2025 07
- Femasys Secures FDA Approval to Advance Final FemBloc® - GlobeNewswire Mon, 03 Nov 2025 08
- PharmaCyte Biotech (Nasdaq: PMCB) Now Holds ~$20M Cash, $25M in Marketable Securities - Stock Titan ue, 25 Nov 2025 08
- Femasys stock rises on new distribution partnership in Switzerland - Investing.com ue, 03 Feb 2026 08
- Femasys Inc. to Showcase Innovative Fertility Solutions at ASRM 2025 Scientific Congress & Expo | FEMY Stock News - Quiver Quantitative hu, 16 Oct 2025 07
- Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - Yahoo Finance Mon, 25 Aug 2025 07
- New device could make fallopian tube testing simpler for fertility care - Stock Titan hu, 18 Dec 2025 08
- Laidlaw initiates Femasys stock with Buy rating on FemaSeed potential - Investing.com hu, 20 Nov 2025 08
- Femasys Announces Third Quarter Financial Results for 2025 - Yahoo Finance Fri, 14 Nov 2025 08
- Femasys Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance Mon, 11 Aug 2025 07
- Femasys (NASDAQ: FEMY) announces $500K second order for FemBloc in France & Benelux - Stock Titan Sat, 11 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -16.33M | -13.17M | -10.49M | -6.55M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.82M | -14.25M | -11.39M | -7.54M |
| ReconciledDepreciation | 872.00K | 907.99K | 889.14K | 964.29K |
| ReconciledCostOfRevenue | 544.90K | 380.07K | 114.03K | 370.38K |
| EBITDA | -16.33M | -13.17M | -10.49M | -6.55M |
| EBIT | -17.20M | -14.08M | -11.37M | -7.51M |
| NetInterestIncome | -1.02M | 265.63K | 214.70K | -15.46K |
| InterestExpense | 1.60M | 165.39K | 13.46K | 19.23K |
| InterestIncome | 582.35K | 431.02K | 228.16K | 3.77K |
| NormalizedIncome | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.82M | -14.25M | -11.39M | -7.54M |
| TotalExpenses | 19.41M | 15.58M | 12.81M | 9.52M |
| TotalOperatingIncomeAsReported | -17.79M | -14.51M | -11.60M | -8.34M |
| DilutedAverageShares | 22.27M | 15.38M | 11.82M | 6.71M |
| BasicAverageShares | 22.27M | 15.38M | 11.82M | 6.71M |
| DilutedEPS | -0.85 | -0.93 | -0.96 | -1.12 |
| BasicEPS | -0.85 | -0.93 | -0.96 | -1.12 |
| DilutedNIAvailtoComStockholders | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeCommonStockholders | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncome | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeIncludingNoncontrollingInterests | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeContinuousOperations | -18.82M | -14.25M | -11.39M | -7.54M |
| TaxProvision | 9.60K | 4.34K | 6.30K | 4.00K |
| PretaxIncome | -18.81M | -14.24M | -11.39M | -7.53M |
| OtherIncomeExpense | -2.31K | 818.42K | ||
| OtherNonOperatingIncomeExpenses | -2.31K | 818.42K | ||
| NetNonOperatingInterestIncomeExpense | -1.02M | 265.63K | 214.70K | -15.46K |
| InterestExpenseNonOperating | 1.60M | 165.39K | 13.46K | 19.23K |
| InterestIncomeNonOperating | 582.35K | 431.02K | 228.16K | 3.77K |
| OperatingIncome | -17.79M | -14.51M | -11.60M | -8.34M |
| OperatingExpense | 18.87M | 15.20M | 12.36M | 9.15M |
| DepreciationAmortizationDepletionIncomeStatement | 297.32K | 483.48K | 561.23K | 591.07K |
| DepreciationAndAmortizationInIncomeStatement | 297.32K | 483.48K | 561.23K | 591.07K |
| ResearchAndDevelopment | 8.22M | 7.21M | 5.81M | 4.08M |
| SellingGeneralAndAdministration | 10.36M | 7.51M | 5.99M | 4.47M |
| SellingAndMarketingExpense | 4.03M | 650.13K | 558.85K | 208.74K |
| GeneralAndAdministrativeExpense | 6.33M | 6.86M | 5.43M | 4.26M |
| OtherGandA | 6.33M | 6.86M | 5.43M | 4.26M |
| GrossProfit | 1.08M | 691.90K | 764.28K | 809.30K |
| CostOfRevenue | 544.90K | 380.07K | 441.94K | 370.38K |
| TotalRevenue | 1.63M | 1.07M | 1.21M | 1.18M |
| OperatingRevenue | 1.63M | 1.07M | 1.21M | 1.18M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 117.22K | 117.22K | 117.22K | 117.22K |
| OrdinarySharesNumber | 23.36M | 21.66M | 11.87M | 11.80M |
| ShareIssued | 23.47M | 21.77M | 11.99M | 11.92M |
| NetDebt | 1.95M | |||
| TotalDebt | 7.44M | 6.70M | 543.72K | 1.01M |
| TangibleBookValue | 2.24M | 18.35M | 15.24M | 26.31M |
| InvestedCapital | 7.71M | 22.61M | 15.38M | 26.53M |
| WorkingCapital | -560.42K | 20.12M | 12.60M | 23.94M |
| NetTangibleAssets | 2.24M | 18.35M | 15.24M | 26.31M |
| CapitalLeaseObligations | 2.04M | 2.44M | 402.42K | 809.09K |
| CommonStockEquity | 2.30M | 18.35M | 15.24M | 26.33M |
| TotalCapitalization | 2.30M | 22.61M | 15.24M | 26.33M |
| TotalEquityGrossMinorityInterest | 2.30M | 18.35M | 15.24M | 26.33M |
| StockholdersEquity | 2.30M | 18.35M | 15.24M | 26.33M |
| OtherEquityInterest | 1.86M | 2.79M | 567.97K | 702.49K |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | |||
| TreasuryStock | 60.00K | 60.00K | 60.00K | 60.00K |
| RetainedEarnings | -127.20M | -108.38M | -94.13M | -82.74M |
| AdditionalPaidInCapital | 127.68M | 123.99M | 108.86M | 108.42M |
| CapitalStock | 23.47K | 21.77K | 11.99K | 11.92K |
| CommonStock | 23.47K | 21.77K | 11.99K | 11.92K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 10.14M | 9.40M | 1.65M | 2.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.56M | 6.35M | 125.24K | 552.21K |
| OtherNonCurrentLiabilities | 39.61K | 54.94K | 96.66K | 149.79K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.52M | 6.29M | 28.58K | 402.42K |
| LongTermCapitalLeaseObligation | 1.52M | 2.04M | 28.58K | 402.42K |
| LongTermDebt | 4.26M | |||
| CurrentLiabilities | 8.58M | 3.05M | 1.53M | 1.69M |
| OtherCurrentLiabilities | 88.58K | 65.30K | 45.21K | 36.04K |
| CurrentDebtAndCapitalLeaseObligation | 5.92M | 406.64K | 515.13K | 606.74K |
| CurrentCapitalLeaseObligation | 517.97K | 406.64K | 373.83K | 406.67K |
| CurrentDebt | 5.41M | 141.30K | 200.07K | |
| OtherCurrentBorrowings | 5.41M | 186.50K | 200.07K | |
| CurrentNotesPayable | 0.00 | 141.30K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 650.77K | 1.08M | 85.19K | 98.27K |
| PayablesAndAccruedExpenses | 1.92M | 1.50M | 882.28K | 951.04K |
| CurrentAccruedExpenses | 500.28K | 349.53K | 344.64K | 402.50K |
| Payables | 1.42M | 1.15M | 537.64K | 548.54K |
| TotalTaxPayable | 0.00 | 12.16K | 26.89K | 103.02K |
| AccountsPayable | 1.42M | 1.14M | 510.76K | 445.52K |
| TotalAssets | 12.45M | 27.76M | 16.90M | 28.58M |
| TotalNonCurrentAssets | 4.42M | 4.58M | 2.76M | 2.95M |
| OtherNonCurrentAssets | 954.99K | 1.09M | 958.18K | 655.42K |
| GoodwillAndOtherIntangibleAssets | 65.92K | 0.00 | 3.29K | 25.09K |
| OtherIntangibleAssets | 65.92K | 3.29K | 25.09K | |
| NetPPE | 3.40M | 3.49M | 1.80M | 2.26M |
| AccumulatedDepreciation | -3.74M | -3.55M | -3.22M | -2.72M |
| GrossPPE | 7.14M | 7.04M | 5.02M | 4.99M |
| Leases | 1.24M | 1.21M | 1.20M | 1.16M |
| ConstructionInProgress | 762.45K | 423.08K | 413.84K | 379.71K |
| OtherProperties | 1.81M | 2.38M | 319.56K | 665.75K |
| MachineryFurnitureEquipment | 3.34M | 3.02M | 3.09M | 2.79M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.02M | 23.18M | 14.13M | 25.63M |
| OtherCurrentAssets | 1.04M | 695.88K | 655.36K | 555.85K |
| Inventory | 3.05M | 667.12K | 436.72K | 208.27K |
| FinishedGoods | 754.83K | 170.19K | 91.77K | 83.94K |
| WorkInProcess | 982.63K | 128.99K | 100.45K | 12.79K |
| RawMaterials | 1.31M | 367.93K | 244.50K | 111.53K |
| Receivables | 488.37K | 98.91K | 77.47K | 84.26K |
| AccountsReceivable | 488.37K | 98.91K | 77.47K | 84.26K |
| AllowanceForDoubtfulAccountsReceivable | -10.00K | -2.00K | -2.05K | -2.03K |
| GrossAccountsReceivable | 498.37K | 100.91K | 79.52K | 86.28K |
| CashCashEquivalentsAndShortTermInvestments | 3.45M | 21.72M | 12.96M | 24.78M |
| CashAndCashEquivalents | 3.45M | 21.72M | 12.96M | 24.78M |
| CashEquivalents | 3.45M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -20.29M | -11.42M | -11.14M | -8.24M |
| RepaymentOfDebt | 0.00 | -626.53K | -528.26K | -462.95K |
| IssuanceOfDebt | 0.00 | 6.85M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 2.03M | 11.56M | 59.58K | 31.74M |
| CapitalExpenditure | -847.76K | -143.92K | -407.48K | -306.87K |
| InterestPaidSupplementalData | 111.00K | 9.90K | 13.46K | 15.87K |
| IncomeTaxPaidSupplementalData | 5.71K | 4.55K | 5.05K | 800.00 |
| EndCashPosition | 3.45M | 21.72M | 12.96M | 24.78M |
| BeginningCashPosition | 21.72M | 12.96M | 24.78M | 3.32M |
| ChangesInCash | -18.26M | 8.75M | -11.82M | 21.46M |
| FinancingCashFlow | 2.03M | 20.18M | -681.64K | 29.70M |
| CashFlowFromContinuingFinancingActivities | 2.03M | 20.18M | -681.64K | 29.70M |
| NetOtherFinancingCharges | -60.75K | -1.30M | -232.84K | -1.58M |
| ProceedsFromStockOptionExercised | 63.11K | 3.69M | 19.88K | |
| NetCommonStockIssuance | 2.03M | 11.56M | 59.58K | 31.74M |
| CommonStockIssuance | 2.03M | 11.56M | 59.58K | 31.74M |
| NetIssuancePaymentsOfDebt | 0.00 | 6.22M | -528.26K | -462.95K |
| NetLongTermDebtIssuance | 0.00 | 6.22M | -528.26K | -462.95K |
| LongTermDebtPayments | 0.00 | -626.53K | -528.26K | -462.95K |
| LongTermDebtIssuance | 0.00 | 6.85M | 0.00 | 0.00 |
| InvestingCashFlow | -847.76K | -143.92K | -407.48K | -306.87K |
| CashFlowFromContinuingInvestingActivities | -847.76K | -143.92K | -407.48K | -306.87K |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -86.06K | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -86.06K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -761.71K | -143.92K | -407.48K | -306.87K |
| PurchaseOfPPE | -761.71K | -143.92K | -407.48K | -306.87K |
| OperatingCashFlow | -19.44M | -11.28M | -10.73M | -7.93M |
| CashFlowFromContinuingOperatingActivities | -19.44M | -11.28M | -10.73M | -7.93M |
| ChangeInWorkingCapital | -3.14M | 1.23M | -458.27K | -732.72K |
| ChangeInOtherCurrentLiabilities | -443.20K | -417.59K | -446.53K | -439.20K |
| ChangeInOtherCurrentAssets | 295.86K | 475.99K | ||
| ChangeInPayablesAndAccruedExpense | 214.23K | 1.61M | -81.84K | -733.61K |
| ChangeInAccruedExpense | 6.75K | 987.58K | -147.07K | -504.80K |
| ChangeInPayable | 207.48K | 627.07K | 65.24K | -228.81K |
| ChangeInAccountPayable | 207.48K | 627.07K | 65.24K | -228.81K |
| ChangeInPrepaidAssets | -139.14K | 282.17K | 295.86K | |
| ChangeInInventory | -2.38M | -230.40K | -232.55K | -77.43K |
| ChangeInReceivables | -397.47K | -21.44K | 6.79K | 41.53K |
| ChangesInAccountReceivables | -397.47K | -21.44K | 6.79K | 41.53K |
| OtherNonCashItems | 1.19M | 107.96K | -821.51K | |
| StockBasedCompensation | 444.15K | 675.70K | 224.94K | 193.37K |
| ProvisionandWriteOffofAssets | 8.00K | 0.00 | 4.10K | 540.00 |
| AmortizationOfSecurities | 0.00 | |||
| DepreciationAmortizationDepletion | 872.00K | 907.99K | 889.14K | 964.29K |
| DepreciationAndAmortization | 872.00K | 907.99K | 889.14K | 964.29K |
| AmortizationCashFlow | 20.14K | 3.29K | 21.80K | 39.98K |
| AmortizationOfIntangibles | 20.14K | 3.29K | 21.80K | 39.98K |
| Depreciation | 851.86K | 904.69K | 867.34K | 924.31K |
| OperatingGainsLosses | 676.00 | 47.54K | 2.29K | -818.42K |
| GainLossOnSaleOfPPE | 676.00 | 47.54K | 2.29K | 3.10K |
| NetIncomeFromContinuingOperations | -18.82M | -14.25M | -11.39M | -7.54M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FEMY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|